ArticleThe Journal of clinical endocrinology and metabolism2026
TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Triiodothyroacetic acid exerts tissue-specific thyromimetic effects without tachycardia and hyperthermia in male mice.European thyroid journal · 2026Article
- TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β.The Journal of clinical endocrinology and metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
contextThe treatment of resistance to thyroid hormone β (RTHβ) is challenging because features of hyperthyroidism in some tissues coexist with a hormone-resistant, hypothyroid state in other organs.
objectiveTo determine whether triiodothyroacetic acid (TRIAC) therapy alleviates hyperthyroid symptoms and changes circulating thyroid hormones, resting energy expenditure and metabolic parameters in RTHβ.
designRetrospective cohort study.
settingReferral center.
participantsEight adult patients with RTHβ (mean age 41 years; 4 males, 4 females).
main outcome measuresHyperthyroid Symptom Scale (HSS) score, serum free T4 and total T3, resting energy expenditure, sleeping heart rate, fasting lipids, and glucose and systemic insulin resistance.
resultsFrom abnormally elevated levels prior to treatment, TRIAC therapy lowered HSS scores (baseline 17.5 vs posttreatment 6; P = .0014), showed a reduced resting energy expenditure trend (baseline Z-score +1.3 vs posttreatment +0.89; P = .38) and normalized circulating free T4 (baseline free T4 30 pmol/L vs posttreatment 17 pmol/L; P = .007) and total T3 (baseline 2.5 nmol/L vs posttreatment 1.4 nmol/L; P = .001) concentrations in 7 out of 8 patients, without any rise in their serum TSH (baseline 2.1 mU/L vs posttreatment 1.7 mU/L; P = .65), total cholesterol (baseline 4.9 mmol/L vs posttreatment 4.8 mmol/L; P = .81), and triglyceride (baseline 1.3 mmol/L vs post-treatment 1.3 mmol/L; P = .44). Their mean sleeping heart rate (baseline 60 bpm vs posttreatment 58 bpm; P = .56) and plasma N-terminal pro-brain natriuretic peptide (baseline 55 ng/L vs posttreatment 54 ng/L) were unchanged. TRIAC treatment was well tolerated, with no side effects.
conclusionTRIAC therapy in RTHβ relieves hyperthyroid symptoms and lowers resting energy expenditure and circulating thyroid hormones without worsening hepatic hormone resistance or exacerbating cardiac thyromimetic activity. Future clinical trials to determine whether TRIAC treatment alters adverse cardiovascular outcomes in this disorder are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.